SPRINT-CKD
2017
Systolic Blood Pressure Intervention Trial — chronic kidney disease subgroup
In 2,646 participants with chronic kidney disease, an intensive systolic-BP target below 120 mmHg reduced all-cause mortality compared with a target below 140 mmHg.
Result
Efficacy: Cardiovascular composite; all-cause mortalityHR 0.72 (CI 0.53-0.99)
Below 1 favours intensive systolic-BP target below 120 mmHg, above 1 favours a target below 140 mmHg.
Also reported: CV composite HR 0.81 (0.63–1.05) and kidney outcome HR 0.90 (0.44–1.83) (both NS).
- Subtopic
- Blood-pressure targets
- Design
- Prespecified subgroup of an open-label RCT
- Relevance
- Important: one of several pillars.
- Source
- Cheung AK, et al. J Am Soc Nephrol. 2017;28(9):2812-2823.doi 10.1681/ASN.2017020148
Discussion & critique
Underpins the KDIGO 2021 target of SBP <120 mmHg by standardised measurement; people with diabetes, polycystic kidneys and proteinuria >1 g/day were excluded.